Ultralife GAAP EPS of $0.14, revenue of $48.3M
Ultralife (ULBI) reported Q3 GAAP EPS of $0.14, with revenue of $48.3M, up 11.3% year-over-year. Adjusted EBITDA was $5.6M, and backlog increased to $136.0M from $117.5M in Q2 2026, according to the company.
How this was made
The 30-second read
Why it matters
The earnings release provides the first quantitative update for the quarter, offering traders a basis for short‑term positioning.
Market read
While the absolute numbers are small, the fresh earnings data creates a trading opportunity for the stock.
What to watch
Potential supply‑chain constraints or upcoming regulatory approvals could affect future performance.
Background
Ultralife (NASDAQ: ULBI) is a micro‑cap medical‑device company that released its third‑quarter 2026 financial results.
Ticker impact
Ultralife reported Q3 GAAP EPS of $0.14, revenue of $48.3M and adjusted EBITDA of $5.6M, marking its first public earnings disclosure for the quarter.
possible modest upside as investors price in improved profitability, but limited by micro‑cap liquidity.
New earnings data provides fresh valuation input; however, the company’s small size and limited analyst coverage constrain the magnitude of the move.
Market effects
Ultralife operates in the medical‑device/health‑tech niche; its earnings may signal demand trends for similar micro‑cap innovators.
Primarily U.S. investors; limited broader regional effect.
Low global impact due to company size.
Counterpoint
Despite earnings growth, the stock may face pressure if revenue guidance is not raised, given its modest scale.
Key entities
- CompanyUltralife Corp.
Medical‑device manufacturer reporting Q3 2026 results.


